At a Glance
- Tasks: Develop innovative bioprocess strategies for therapeutic nucleoside editing.
- Company: The University of Manchester, renowned for its research excellence.
- Benefits: Fully funded PhD, access to cutting-edge facilities, and collaborative research opportunities.
- Other info: Exciting opportunity to contribute to groundbreaking scientific advancements.
- Why this job: Join a pioneering project that could revolutionise therapeutic treatments.
- Qualifications: Strong background in chemistry and a passion for research.
The predicted salary is between 32918 - 40233 £ per year.
The University of Manchester’s School of Chemistry invites applications for a fully funded PhD studentship in Bioprocess: Skeletal Editing of Therapeutic Nucleosides. This 3.5-year programme starts in 2026 and focuses on developing bioprocess strategies and skeletal editing to create novel therapeutic nucleosides, integrating synthesis, analytics, and biocatalysis within a collaborative research environment.
PhD in Bioprocess Chemistry: Therapeutic Nucleoside Editing in Manchester employer: RFCSR
At King’s College London, we pride ourselves on being an exceptional employer that fosters a collaborative and innovative work culture. Our interdisciplinary approach not only encourages professional growth through diverse research opportunities but also allows you to make a meaningful impact in the fields of engineering and biomedical research. Located in the vibrant city of London, our institution offers a dynamic environment where creativity thrives and employees are supported in their career development.
